Yes, it seems an awful lot for the current program given that...

Yes, it seems an awful lot for the current program given that total research and development costs last year were under $5m, they are half way through the trial, and they have @ $25m in cash left. Either there has been a complete blow-out of costs due to having to manufacture additional compound, or they are planning more than one trial. They have mentioned an additional $3m towards scale up of manufacturing though and I would assume that includes compound for the current trial.

There are only another 8 patients left to dose, so an explanation of why this is costing so much would be appreciated.